CordovaCann Corp.
CordovaCann Corp. is a cannabis-focused company engaged in the identification, acquisition, and organization of cannabis operations across North America. This company's primary function is to build a diversified portfolio of assets—each contributing to a wide-reaching network within the rapidly evolving cannabis industry. CordovaCann Corp. has strategically positioned itself within crucial cannabis markets, encompassing both cultivation and distribution sectors, which are pivotal for tapping into emerging market opportunities and regulatory frameworks. The firm is known for its flexible investment strategy, which includes both direct and indirect stakes in cannabis-related enterprises. By focusing on markets like Canada and the United States, CordovaCann Corp. leverages its market presence to enhance consumer access to cannabis and its derivative products. Its role in the financial market is significant, as it supports the expansion and innovation of a sector that is seeing increasing legal and societal acceptability. Through its ventures, CordovaCann Corp. contributes to the development of a comprehensive and sustainable cannabis ecosystem, facilitating the growth and scaling of operations in a competitive yet promising industry.
$0.03
+$0.00 (+0.00%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-1.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 3.3%, steady but not accelerating. Free cash flow declined 25% despite revenue growth, conversion is weakening.
Free cash flow declined 25% versus the prior year, cash generation momentum has weakened.
1.7x earnings, 4.2x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$18M
▲ +3.3% YoY
Net Income (TTM)
C$131K
▼ -92.5% YoY
Op. Margin
10.84%
▲ +3.2pp YoY
ROIC
-2.90%
▲ +5.2pp YoY
Cash Flow & Balance Sheet
FCF (FY)
C$1M
▼ -24.8% YoY
Op. Cash Flow (FY)
C$1M
▼ -23.7% YoY
Net Debt
C$4M
Cash & Equiv.
C$598K
3Y CAGR: +1.8%
Continue Research
Is CordovaCann (LVRLF) overvalued?
At a P/E of 1.7 and a price-to-free-cash-flow of 4.2, CordovaCann (LVRLF) trades below a two-stage DCF intrinsic value of about C$0.14 per share, so at C$0.03 the stock looks undervalued (357.6% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, CordovaCann scores 51/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is CordovaCann's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about C$0.14 per share for LVRLF, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around C$0.10. At today's C$0.03, that puts the stock about 357.6% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is CordovaCann a high-quality business?+
CordovaCann scores 51 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 10.8% operating margin and a -2.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is CordovaCann a good stock to buy right now?+
That depends on valuation and quality together, not either alone. LVRLF currently trades below its estimated intrinsic value and scores 51/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.